Evidence map›Paper›PMID 37755983›Full record

ArticleToxins2023

Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and Papuan

Lyndi L Gilliam, John Gilliam, Stephen P Samuel, Rebecca W Carter, Jerry Ritchey, Tommaso Bulfone, José María Gutiérrez, David J Williams, Daniela M Durkin, Sally I Stephens and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Toxicon: X · 2026
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Lyndi L GilliamDepartment of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
John GilliamDepartment of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Stephen P SamuelDivision of Research Ophirex, Inc., Corte Madera, CA 94925, USA.
Rebecca W CarterDivision of Research Ophirex, Inc., Corte Madera, CA 94925, USA.ORCID 0000-0002-5977-7338
Jerry RitcheyDepartment of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Tommaso BulfoneCenter for Exploration and Travel Health, California Academy of Sciences, San Francisco, CA 94118, USA.
José María GutiérrezInstituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501-2060, Costa Rica.ORCID 0000-0001-8385-3081
David J WilliamsRegulation and Prequalification Department (RPQ) at the World Health Organization (WHO), 1211 Geneva, Switzerland.
Daniela M DurkinCenter for Exploration and Travel Health, California Academy of Sciences, San Francisco, CA 94118, USA.
Sally I StephensDivision of Research Ophirex, Inc., Corte Madera, CA 94925, USA.
Matthew R LewinDivision of Research Ophirex, Inc., Corte Madera, CA 94925, USA.ORCID 0000-0003-4480-9891
Oklahoma State University · USCalifornia Academy of Sciences · USUniversidad de Costa Rica · CRUniversity of California, San Francisco · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Antivenom is currently the standard-of-care treatment for snakebite envenoming, but its efficacy is limited by treatment delays, availability, and in many cases, species specificity. Many of the rapidly lethal effects of envenoming are caused by venom-derived toxins, such as phospholipase A2 (sPLA2); therefore, small molecule direct toxin inhibitors targeting these toxins may have utility as initial and adjunct therapies after envenoming. Varespladib (intravenous, IV) and varespladib-methyl (oral) have been shown to potently inhibit sPLA2s from snake venoms in murine and porcine models, thus supporting their further study as potential treatments for snakebite envenoming. In this pilot study, we tested the ability of these compounds to reverse neurotoxic effects of venom from the Australian and Papuan taipan (

Indexed as

Phospholipases A2, SecretorySnake BitesAcetatesAnimalsAntiveninsAustraliaElapidaeElapid VenomsIndolesKeto AcidsMicePilot ProjectsSwineVenomous SnakesAcetatesAntiveninsElapid VenomsIndolesKeto AcidsPhospholipases A2, Secretoryvarespladibvarespladib methylantivenomcoastal taipandirect toxin inhibitorOxyuranusphospholipase A2 inhibitorssnakebitevarespladibvenom

Identifiers

PMID37755983
PMCPMC10537020
OpenAlexW4386525606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.